Triple therapy inhalers for COPD can reduce exacerbations but may increase pneumonia risk, necessitating careful patient phenotype assessment. Roflumilast and azithromycin effectively reduce COPD ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback